Multiple myeloma (MM) is a clonal plasma cell malignancy affecting a predominantly elderly population. The continued development of newer therapies with novel mechanisms of action has reshaped the treatment paradigm of this disorder in the last two decades, leading to a significantly improved prognosis. Immune-based therapies, including monoclonal antibodies, and more recently also adoptive cellular therapies have emerged as therapeutic strategies in MM. During her lecture at the 2021 BHS GAM, Prof. Maria-Victoria Mateos gave an overview of the current state of affairs related to immune related therapies in MM.
